Research Topics
Species | Katharina BuergerSummaryAffiliation: University of Munich Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairmentKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
J Clin Psychiatry 72:556-63. 2011....- Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratioKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, Munich 80336, Germany
Biol Psychiatry 65:979-84. 2009..We hypothesized that this set of blood-based (micro)circulation parameters is altered in AD... - Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)Katharina Buerger
Department of Psychiatry, Ludwig Maximilian University Munich, Munich, Germany
Exp Gerontol 44:579-85. 2009..Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported... 
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's diseaseKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Department of Psychiatry, Ludwig Maximilian University Munich, Germany
Brain 129:3035-41. 2006..There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease...- Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob diseaseKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
Neurobiol Aging 27:10-5. 2006..Our findings indicate a dissociation in the direction of change in CSF levels of t-tau and p-tau231 in CJD when compared to AD... - Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF studyK Buerger
Memory Clinic, Alzheimer Memorial Center, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
Neurology 65:1502-3. 2005 - Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairmentKatharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
Neurosci Lett 391:48-50. 2005..Our study indicates that the apoE epsilon4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects... - Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid studyHarald Hampel
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
Arch Gen Psychiatry 61:95-102. 2004..Different tau phosphoepitopes can be sensitively detected in cerebrospinal fluid (CSF)... - Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer's diseaseStefan Forster
Department of Nuclear Medicine, Ludwig Maximilian University, Munich, Germany
J Alzheimers Dis 26:337-48. 2011..A six-month cognitive intervention imparted cognitive benefits in patients with aMCI, which were concurrent with an attenuated decline of glucose metabolism in cortical regions affected by neurodegenerative AD... - Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231Katharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
Am J Psychiatry 160:376-9. 2003..The authors asked whether p-tau(231) levels improve the differential diagnosis between geriatric major depression and Alzheimer's disease... - Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot studyVerena C Buschert
Department of Psychiatry Ludwig Maximilians University, Munich, Germany
J Alzheimers Dis 25:679-94. 2011..In contrast, AD patients showed no significant benefit from intervention. The findings in this small sample support the use of the intervention in larger scales studies with an extended follow-up period to determine long-term effects... - Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairmentPhiline Schneider
Alzheimer Memorial Center, Department of Psychiatry, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany
Biol Psychiatry 70:145-51. 2011..Midregional proatrial natriuretic peptide (MR-proANP), an inactive surrogate molecule of the mature atrial natriuretic peptide, is related to circulatory function and hypertension... - Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231Katharina Buerger
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
Arch Neurol 59:1267-72. 2002.... - Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau proteinHarald Hampel
Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Ludwig Maximilian University, D 80336 Munich, Germany
Brain Res Bull 61:243-53. 2003.... - Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's diseaseStefan Forster
Department of Nuclear Medicine, Ludwig Maximilian University, Munich, Germany
J Alzheimers Dis 25:695-706. 2011..A six-month cognitive intervention imparted cognitive benefits in patients with aMCI, which were concurrent with an attenuated decline of glucose metabolism in cortical regions affected by neurodegenerative AD... - Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diseasePeter Schönknecht
Department of Psychiatry, University of Heidelberg, Voss Strasse 4, D 69115, Heidelberg, Germany
Neurosci Lett 339:172-4. 2003..These findings suggest that total and phosphorylated tau protein may facilitate early detection and differential diagnosis of AD... - Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseaseJens Wiltfang
Department of Psychiatry, , Germany
Ann Neurol 54:263-7. 2003..We conclude that the immunoblot shows disease-specific CSF Abeta peptide patterns in CJD and AD and suppose that measurement of the Abeta peptide pattern seems to be a promising diagnostic tool in the differential diagnosis of dementias... - Biological marker candidates of Alzheimer's disease in blood, plasma, and serumPhiline Schneider
Department of Psychiatry, Ludwig Maximilian University, Alzheimer Memorial Center, Munich, Germany
CNS Neurosci Ther 15:358-74. 2009..The status and emerging perspectives on hypothesis and exploratory-based candidate biomarkers derived from blood, plasma, and serum are reviewed and discussed... - Reliable manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic resonance images of healthy subjectsArun L W Bokde
Dementia and Neuro-imaging Research Section, Alzheimer's Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstr. 7, Station D2, 80336 Munich, Germany
Brain Res Brain Res Protoc 14:135-45. 2005..55% to 3.09% (from 0.94 to 0.99). CONCLUSION: This technique has been shown to have high intra- and inter-rater reliability. The current method provides a method to obtain volumetric estimates of the 4 cerebral lobes... - Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's diseaseStefan J Teipel
Department of Psychiatry, University of Rostock, Rostock, Germany
J Alzheimers Dis 33:S329-47. 2013..Critical testing of these predictions will help us to modify or even falsify the currently hold assumptions on the pathogenesis of AD based on in vivo evidence in humans... - Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmasMuamer Omerovic
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
World J Biol Psychiatry 9:69-75. 2008..Furthermore, we discuss current difficulties regarding AD treatment by looking for explanations for a still unsatisfying rate of state-of-the-art treatment of AD-patients... - Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementiaStefan Lorenzl
Department of Neurology and Neurosience, Weill Medical College of Cornell University, New York, USA
Int Psychogeriatr 20:67-76. 2008.... - Functional representation of olfactory impairment in early Alzheimer's diseaseStefan Forster
Department of Nuclear Medicine, Ludwig Maximilian University, Munich, Germany
J Alzheimers Dis 22:581-91. 2010.... - Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's diseaseAnnica Johansson
Department of Clinical Neuroscience, Unit of Neurochemistry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
Dement Geriatr Cogn Disord 20:367-74. 2005..006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD... - Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patientsAnnika Olsson
Institute of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Exp Neurol 183:74-80. 2003..Neither the levels of CSF-beta-sAPP nor CSF-Abeta(42) differed when comparing ApoE4 allele-positive with allele-negative individuals... - Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's diseaseRichard Dodel
Department of Neurology, Philipps University Marburg, Germany
Ann Neurol 52:253-6. 2002..This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease... - No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's diseaseKatharina Buerger
Brain 130:e82. 2007 - Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammationAndrea Ernst
SphingoTec GmbH, Tulpenweg 6, D 16556 Borgsdorf, Germany
J Neuroimmunol 189:169-74. 2007..Our results indicate a central production of PCT and suggest PCT as a valuable marker candidate for the monitoring of dementia and acute neuroinflammation...